Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non–Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery

Santarpía, Mariacarmela; Ramirez, José Luis; Aguirre, Itziar de; Garrido, Pilar; Cano, Maria Pérez; Queralt, Cristina; Gonzalez-Larriba, J. L.; Insa, Amelia; Provencio, Mariano; Isla, Dolores; Camps, Carlos; Blanco, Remei; Morán, Teresa; Rosell, Rafael

doi:10.1016/j.cllc.2016.08.007

Cited by 5 publications

(5 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this case, the DNA repair capacity in tumour cells has an immense impact on clinical efficacy in NSCLC patients who receive platinum-based chemotherapeutics. 30,31 ERCC1 as a highly conserved structure-specific time in contrast to those carrying C allele, consistently with the previous reports. 35,36 The rs3212986 polymorphism showed a close relationship with the overall survival and prognosis in advanced NSCLC patients treated with platinum-based chemotherapy.…”

Section: Discussionsupporting

confidence: 92%

“…As known, the pharmacological role of platinum‐based chemotherapeutics is to form platinum‐DNA adducts, which will lead to the inhibition of proliferation in tumour cells. In this case, the DNA repair capacity in tumour cells has an immense impact on clinical efficacy in NSCLC patients who receive platinum‐based chemotherapeutics 30,31 . ERCC1 as a highly conserved structure‐specific endonuclease, functions in the NER pathway and cuts the damaged strand from 5′ to the site of damage 32 and its polymorphisms have been widely studied and gradually regarded as biomarkers to predict the risk and prognosis of multiple cancers.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A miR‐15a related polymorphism affects NSCLC prognosis via altering ERCC1 repair to platinum‐based chemotherapy

Xue

Zhang

et al. 2022

J Cellular Molecular Medi

View full text Add to dashboard Cite

Platinum-based chemotherapy is regarded as a preferential curative-intent option for non-small cell lung cancer (NSCLC), while the acquired drug resistance has become a major obstacle that limits its clinical application. Since the repair efficiency of tumour cells to platinum-DNA adducts plays a crucial role in chemotherapy resistance, we aimed to explore whether several meaningful polymorphisms of DNA repair genes were associated with the benefits of platinum-based chemotherapy in NSCLC patients. Firstly, six single nucleotide polymorphisms (SNPs) located in the 3'untranslated region (3'UTR) of three DNA repair genes were detected in 246 NSCLC patients receiving platinum-based chemotherapy and analysed the correlation of these candidate SNPs with the overall survival. Cox proportional hazard model showed that NSCLC patients carrying ERCC1 rs3212986 AA genotype had a shorter overall survival compared to those with CC. Mechanistically, we performed tumour chemosensitivity assay to observe the convincing linkage of rs3212986 polymorphism with ERCC1 expression and cisplatin sensitivity. The subsequent in vitro experiments identified that rs3212986 polymorphism altered the post-transcriptional regulation of ERCC1 via affecting the binding of miR-15a, and further changed the sensitivity to platinum analogue. It reminded that patients carrying ERCC1 rs3212986 CC homozygote were expected to respond better to platinum-based chemotherapy due to a lower expression of ERCC1. Compared with previous studies, our current comprehensive study suggested that rs3212986, a 3'UTR polymorphism in ERCC1, might have clinical relevance in predicting the prognosis of NSCLC patients receiving platinum-based chemotherapy.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

A miR‐15a related polymorphism affects NSCLC prognosis via altering ERCC1 repair to platinum‐based chemotherapy

Xue

Zhang

et al. 2022

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…Interestingly, after incorporating data from recent publications [ 21 , 45 , 68 ], we identified several new significant associations that were not found to be statistically significant in the previous meta-analysis by Tan et al These include variants in genes involved in DNA repair ( ERCC2 rs1799793, XRCC1 rs25487, and XPC rs77907221). The variant allele of ERCC2 rs1799793 showed associations with PBC chemoresistance, supporting the findings of a previous meta-analysis by Qiu et al [ 69 ] .…”

Section: Discussionmentioning

confidence: 88%

Genetic Variants Associated With Response to Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer Patients: A Field Synopsis and Meta‐Analysis

Sito,

Sharzehan,

Islam

et al. 2024

Br J Biomed Sci

View full text Add to dashboard Cite

Background: Publications on the associations of genetic variants with the response to platinum-based chemotherapy (PBC) in NSCLC patients have surged over the years, but the results have been inconsistent. Here, a comprehensive meta-analysis was conducted to combine eligible studies for a more accurate assessment of the pharmacogenetics of PBC in NSCLC patients.Methods: Relevant publications were searched in PubMed, Scopus, and Web of Science databases through 15 May 2021. Inclusion criteria for eligible publications include studies that reported genotype and allele frequencies of NSCLC patients treated with PBC, delineated by their treatment response (sensitive vs. resistant). Publications on cell lines or animal models, duplicate reports, and non-primary research were excluded. Epidemiological credibility of cumulative evidence was assessed using the Newcastle-Ottawa Scale (NOS) and Venice criteria. Begg’s and Egger’s tests were used to assess publication bias. Cochran’s Q-test and I2 test were used to calculate the odds ratio and heterogeneity value to proceed with the random effects or fixed-effects method. Venice criteria were used to assess the strength of evidence, replication methods and protection against bias in the studies.Results: A total of 121 publications comprising 29,478 subjects were included in this study, and meta-analyses were performed on 184 genetic variants. Twelve genetic variants from 10 candidate genes showed significant associations with PBC response in NSCLC patients with strong or moderate cumulative epidemiological evidence (increased risk: ERCC1 rs3212986, ERCC2 rs1799793, ERCC2 rs1052555, and CYP1A1 rs1048943; decreased risk: GSTM1 rs36631, XRCC1 rs1799782 and rs25487, XRCC3 rs861539, XPC rs77907221, ABCC2 rs717620, ABCG2 rs2231142, and CDA rs1048977). Bioinformatics analysis predicted possible damaging or deleterious effects for XRCC1 rs1799782 and possible low or medium functional impact for CYP1A1 rs1048943.Conclusion: Our results provide an up-to-date summary of the association between genetic variants and response to PBC in NSCLC patients.

show abstract

“…Many studies show that the risk of lung cancer, therapeutic efficacy, and prognosis is tightly correlated with SNP loci of many genes (Sato et al, 2011;Han et al, 2013Han et al, , 2014Yoon et al, 2014;Tang et al, 2015). Some studies focused on the DNA damage repair-related genes, such as XRCC1 (Tiseo et al, 2013), ERCC1 (Ren et al, 2012), TP53, PARP1 (Shiraishi et al, 2010), and XPD (Santarpia et al, 2017) in NSCLC, etc. Our group has found that rs12334811, rs11615, and rs2299939 in DNA repair pathway genes might regulate the expression and affect the DNA damage repair and thereby impact the efficacy of radio-chemotherapy and the survival time of NSCLC (Wang et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

Association of PTEN Gene SNPs rs2299939 With PFS in Patients With Small Cell Lung Cancer Treated With Early Radiotherapy

et al. 2020

View full text Add to dashboard Cite

Lung cancer has higher morbidity and mortality than most cancers. It is common that there are some phenomenons of secondary drug resistance, radiotherapy resistance and poor prognosis during the treatment of small cell lung cancer (SCLC). Recent studies revealed that the single-nucleotide polymorphisms (SNPs) are associated with the curative effect among patients with the same pathological type and stage. Our study analyzed the start time of radiotherapy and the relationship between PTEN gene rs2299939 polymorphisms and survival time among 116 SCLC patients. The results showed that early radiotherapy significantly improved the time of survival in patients compared with late radiotherapy (P = 0.029). Simultaneously, the study found that patients with the rs2299939 AA genotype showed significant sensitivity to both early and late radiotherapy, but early radiotherapy is better. The median survival time of CC genotype patients was 12 months in the early radiotherapy group while it was 9 months in the late radiotherapy group, thus recommending early radiotherapy among these patients. In addition, it was found that rs2299939 could regulate the expression of related genes in peripheral blood and lung tissues by eQTL analysis. This study revealed that the early radiotherapy could prolong the PFS of SCLC and shall be performed in SCLC treatment.

show abstract

Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non–Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery

Cited by 5 publications

References 40 publications

A miR‐15a related polymorphism affects NSCLC prognosis via altering ERCC1 repair to platinum‐based chemotherapy

A miR‐15a related polymorphism affects NSCLC prognosis via altering ERCC1 repair to platinum‐based chemotherapy

Genetic Variants Associated With Response to Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer Patients: A Field Synopsis and Meta‐Analysis

Association of PTEN Gene SNPs rs2299939 With PFS in Patients With Small Cell Lung Cancer Treated With Early Radiotherapy

Contact Info

Product

Resources

About